Introduction
Anorexia nervosa can devastate medical, psychological and social adjustments, and despite treatment advances, only about half of people with the condition achieve full remission after 10 or more years. 1 Such realities point to the need for improved knowledge of the causal and maintaining factors of what can be an insidious disorder.
Anorexia nervosa is understood to have multiple determi nants, including genetic factors (shaping such processes as emotion regulation, reward sensitivity and energy metab olism), environmental triggers (including perinatal, develop mental and laterlife events), staterelated effects (owing to nutritional and mental status) and social inducements toward intensive caloric restraint. 2, 3 Although twin studies have shown anorexia nervosa to be strongly heritable, efforts to identify syndromerelevant genes have been dis appointing. 4, 5 However, a recent study has documented a genetic locus that reached genomewide significance for anorexia nervosa: a site on chromosome 12 associated with type 1 diabetes and autoimmune diseases. 6 Genetic correla tions associated anorexia nervosa with both mentalillness (schizophrenia and neuroticism) and metabolic (glucose and lipid metabolism) phenotypes. In other words, broad J Psychiatry Neurosci psychiatric, metabolic and autoimmune spheres have been indicated.
Gene-environment interactions and epigenetics
Complex psychiatric syndromes are almost certain to involve the environmental activation of hereditary potentials, and this likely applies to anorexia nervosa: risk of anorexia ner vosa is increased when people who are genetically predis posed experience familial distress. 7 Likewise, animal data suggest that genetic susceptibility, combined with adolescent social stress and caloric restraint, produces a mouse analog to anorexia nervosa: mice that let themselves starve. 8 Diverse environmental influences have been postulated to act in anorexia nervosa, including obstetric insults, gestational stress, childhood trauma, familial conflict and social induce ment toward caloric restraint. 9, 10 Epigenetic processes influence gene expression and cor responding phenotypic variations. 11 Some epigenetic mech anisms appear to be environmentally responsive and consti tute plausible substrates for gene-environment interactions that underlie mentalillness phenotypes, including anorexia nervosa. 6, 10, 12 The beststudied epigenetic mechanism is DNA methylation, which generally reduces gene expression. 11 Research has shown that DNA methylation responds to peri natal insults 13 and earlylife stresses, [14] [15] [16] and is also influ enced by psychotherapeutic, nutritional and pharmacologic interventions. [17] [18] [19] If so, DNA methylation could be a marker of disease staging or therapeutic response.
DNA methylation in anorexia nervosa
An accumulating literature has associated anorexia nervosa with altered DNA methylation. 5, 6, 10 Candidategene studies have linked anorexia nervosa to hypermethylation of genes for αsynuclein (involved in neurotransmitter release), 20 natriuretic peptide (implicated in anxiety, depression and stress responses), 21 dopamine function (implicated in reward sensitivity and bingeeating) 22 and oxytocin (linked to attach ment). 23 Other studies in anorexia nervosa have estimated global DNA methylation levels, although they have been lim ited by small samples or methods that interrogate narrow genomic regions. One study, using DNA from peripheral blood obtained from 10 women with anorexia nervosa and 10 without, found no differences when comparing methylation of LINE1 repetitive elements (a proxy for global methyla tion). 24 Two other studies, 1 involving 22 adults with anorexia nervosa (subtype unspecified) 20 and another involving 32 ado lescents with anorexia nervosa, restricting type, 25 reported lower global methylation; the first used a nonradio active elongation assay, the second involved incorporation of [ 3 H]dCTP following a cut with HpaII. Because global methylation measures provide a rather blunt indicator of possible epigenetic effects, genespecific methylation differences assessed using microarray technol ogies are likely to be more informative. We recently used a highthroughput technology (Infinium Human Methylation 450 BeadChip Kit; Illumina Inc.) and DNA in leukocytes from 29 women with anorexia nervosa and 15 women with out anorexia nervosa and within a healthy weight range to perform a genomewide examination of methylation levels. 26 Case-control comparisons with false discovery rate (FDR) corrections identified 14 differentially methylated CpG probes, corresponding to genes acting in histone acetylation, cholesterol storage, lipid transport and dopamine and gluta mate signalling. Findings also linked the chronicity of illness to methylation at 119 genes associated with anxiety, social behaviour, immunity and nervoussystem function. In other words, like the genomewide association study described earlier, 6 our study indicated altered psychiatric, physiologic and immune functions. A subsequent independent study using the same technology compared DNA methylation in 47 women with anorexia nervosa to 100 populationbased controls 27 and identified 81 differentially methylated sites. Both studies isolated the NR1H3 gene (involved in lipid homeostasis and inflammation) and the TNXB gene (associ ated with connectivetissue disorders).
Present study
We extended our investigation of DNA methylation in people with and without anorexia nervosa, increasing sample sizes and adding a sample of women who, when tested, had been free of eatingdisorder symptoms and weightrestored for at least 1 year. We also investigated withinsubject longitudinal changes in methylation levels (attributable to stabilization of symptoms and weight restoration). Our combined prospective/ crosssectional design was intended to help differentiate tran sient illness sequelae from stable epigenetic traits.
Methods
Procedures in this study complied with the ethical standards of relevant institutional committees and the Helsinki Declaration, revised in 2008.
Participants
Participants with an active eating disorder (active group), recruited at a specialized eating disorders program, included 75 women with an anorexia nervosa diagnosis according to DSM5 and a body mass index (BMI) under 18 kg/m 2 . Of these, 34 had anorexia nervosa restrictive type and 41 had anorexia nervosa binge/purge type. Of the total, 29 figured in our earlier report (see Booij and colleagues 26 ). Diagnoses were based on interviews with the Eating Disorders Exami nation (EDE) 28 or clinical interviews conducted by specialist clinicians, complemented by results from the EDE Question naire (EDEQ; 4 cases). 29 We obtained followup methylation and clinical data on 52 women (28 with anorexia nervosa restrictive type and 24 with anorexia nervosa binge/purge type) after an average of 114 days (range 62 to 182 days) of treatment emphasizing weight restoration.
We also recruited 31 women who had previously fulfilled the DSM5 criteria for anorexia nervosa but who, upon entry into the study, did not meet criteria for anorexia nervosa or bulimia nervosa (based on retrospective EDE interviews), and had maintained a selfreported BMI of 18 kg/m 2 or higher for at least 12 months (remitted group).
Excluding people taking medications was impractical and undesirable on grounds of representativeness, so we retained 51 of 75 women (68.0%) in the active group and 10 of 31 women (32.3%) in the remitted group who were taking psychoactive medication. We also retained participants who had mood, anxiety, substance use or personality disorders, but not conditions that would create interpretive confounds (e.g., endocrinologic, diabetic, neoplastic or cardiovascular diseases; substance dependence, psychosis or bipolar illness).
Details of participants' BMI, age, illness characteristics, medication use and cigarette smoking are provided in Table 1 . Groups did not vary according to mean age, but did differ as expected in terms of mean BMI and EDE total scores. The 2 active anorexia nervosa groups showed sig nificantly lower BMI and had significantly more eating dis order symptoms than the other 2 groups did. Compatible with known differences with respect to the prevalence of cigarette smoking, 30 participants with anorexia nervosa binge/purge type were significantly more likely to smoke than members of other groups were (Table 1 ). We con trolled statistically for effects attributable to age and smoking. However, variations related to comorbidity, substance use and medication type rendered application of meaningful statistical controls unrealistic.
We recruited 41 noneatingdisordered (NED) women through public and university/collegebased announcements. These women showed no eating disorder or other psychiatric illnesses according to structured interviews. None of the women in the NED group used psychoactive medications. Data for 15 of the women in the NED group were included in our earlier report. 
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Clinical measures
We assessed eatingdisorder symptoms using the EDE interview 28 and/or the EDEQ. 29 The EDE is a goldstandard interview for assessing anorexic and bulimic symptoms (Cronbach α = 0.67-0.90). The EDEQ is a 41item selfreport questionnaire based on the EDE (α = 0.78-0.93); EDEQ results correspond well to those of the EDE. 31 To estimate chronicity of illness (i.e., time since the onset of clinically significant symptoms of an eating disorder), trained inter viewers established a retrospective portrait of each partici pant's eatingsymptom history and, in reference to EDE diagnostic items, estimated the point at which symptoms became severe enough to support a diagnosis based on DSM5 criteria. We used anthropometric measures to com pute participants' BMI.
Because we started this study before the release of structured interviews based on DSM5, we evaluated psy chiatric comorbidity using the Structured Clinical Inter view for DSMIV (SCIDI) 32 and the Structured Clinical Interview for DSMIV Axis II (SCIDII) 33 modules for bor derline personality disorder and obsessive-compulsive disorder. However, we updated diagnostic determina tions using DSM5 criteria. During study recruitment, we conducted interrater reliability checks on diagnostic de terminations in 25 pseudorandomly chosen interview pairs. Those checks yielded prevalenceadjusted, bias adjusted κ coefficients (used for imbalanced distribution of marginal cell totals 34 ) of 0.84 to 1, and percent agree ments of 92% to 100% (Appendix 1, Table S1 , available at jpn.ca/170242).
Genome-wide DNA methylation analyses
We collected whole blood in EDTA tubes and extracted DNA from leukocytes using a DNA extraction kit (Qiagen). Epigenomewide analyses were conducted at the Genome Quebec Innovation Centre using the Infinium Human Methylation 450 BeadChip Kit (Illumina Inc.; n = 171 samples) or the Infinium MethylationEPIC BeadChip Kit (Illumina Inc.; n = 28 samples). Analyses were per formed according to standard procedures, 26 except that singlebase extension and staining was automated. Samples from the 2 arrays were merged using the combineArrays function in minfi (Bioconductor). The reason different methyl ation array kits were used was that Illumina discon tinued the 450 BeadChip kit. However, manufacturer infor mation and an independent study suggest that samples can be combined across kits. 35 Isolated DNA was first checked for quality with picogreen, and then bisulfiteconverted using the EZ96 DNA MethylationGold Kit (Zymo Research). Next, samples were transferred to BCD and then MSA4 plates, and neutralized before overnight amplifica tion. The MSA4 plates were fragmented, precipitated and resuspended before hybridization and transfer to Multi BeadChips. The Multi BeadChips then underwent washing, singlebase extension and staining before imaging using the HiScan array scanner (Illumina Inc.).
Data processing and data filtering
We processed raw data using R (Bioconductor). We performed quality control using minfi metrics. Functional normaliza tion was applied and values were backgroundcorrected. Pri mary outcome measures were β values at each probe, repre senting the proportion of methylated cells. The specific chromosomal position and associated gene for each probe were defined using manifest files from Illumina (https:// support .illumina.com/downloads/humanmethylation450 _15017482_v1-2_product_files.ilmn). To correct for celltype distribution effects, we applied a statistical correction based on the reference methylation profiles of separated periph eral blood mononuclear cells. 36 The initial data set consisted of 453 093 probes obtained from 147 participants. Because all participants were female, we ignored probes located on the Y chromosome. To remove random technical variations, we retained only CpGs that were associated with known proteincoding genes and with a > 5% deviation in methylation. After functional normaliza tion, we observed possible probewise batch effects (i.e., β values for some probes on a given plate fell far outside the range of β values on all other plates). To eliminate such cases, we removed probes with at least 1 value below the estimated 0.01st percentile or above the estimated 99.99th percentile of the samples on the remaining plates. The final data set for subgroup comparisons and chronicity analyses included 35 513 probes (7.8% of the original probes). The final data set for pre/post comparisons included 37 507 probes (8.2% of the original probes).
We compared groups based on descriptive and clinical variables using χ 2 or 1way analysis of variance (ANOVA) as appropriate, performed with SPSS 23 (SPSS Inc.). We conducted methylation analyses using R. We conducted group comparisons at individual probes using linear mod els, with methylation level as the dependent variable, group as the independent variable and estimated cell pro portions 36 as covariates. We first tested for overall differ ences among groups (active versus remitted versus NED; anorexia nervosa restrictive type versus anorexia nervosa binge/purge type versus NED) using ANOVA, followed by pairwise comparisons where overall effects were signifi cant. We repeated group comparisons with covariates that controlled for age variations and the presence or absence of cigarette smoking. Rare changes in significance levels resulting from application of covariates are annotated in the text and in Table 2 . To examine associations between chronicity and methylation in the active sample, we used linear regression analysis. We used quantile regression to model the effects of median pre/posttreatment differ ences in BMI on pre/post changes in probewise methyla tion levels, with the estimated celltype proportions as a covariate. Quantile regression allowed for the comparison of findings in participants who had achieved substantial pre/post weight gain to those who had not. We applied FDR corrections within each set of analyses (i.e., within ANOVAs, analyses of covariance, pairwise contrasts, linear regression and quantile regression).
Results
Active versus remitted versus NED
A 1way ANOVA for 3 groups showed differential methyla tion (at Q < 0.01) on 373 probes (representing 349 genes). For 295 of these (representing 277 genes), we found at least 1 sig nificant pairwise comparison (at Q < 0.01). The ANOVA and pairwise comparison results for these 295 probes, ranked in order of statistical significance in the ANOVA, can be found in Appendix 1, Table S2 .
Pairwise comparisons between the active and NED groups revealed 58 differentially methylated sites (Q < 0.01), cor responding to 55 genes. Some of the identified genes were linked to nutrition: for example, lipid processing (PRKAG2 [2 probes], SCARF1) and glucose metabolism (RPTOR [2 probes], SORBS1). Others were relevant to bone health (MICAL2) and immune function (FCGR2A, NOD1). One gene was positively associated with serotonin 2B receptor function (HTR2B). According to β values, methylation levels on 53 (91.4%) of the differentially methylated probes were higher in the active group, implying generally reduced expression of implicated genes in anorexia nervosa.
Pairwise comparisons between the active and remitted groups revealed 265 differentially methylated probes (Q < 0.01), corresponding to 252 genes (Appendix 1, Table S2 ). Similar to the active versus NED comparisons, many differ entially methylated probes were linked to genes related to Among the 28 probes that were common to active versus NED and active versus remitted comparisons (representing 9.5% of the 295 identified probes and 10.1% of the 277 identi fied genes), effects across the analyses were always in oppo site directions; that is, when methylation was higher in people with active versus NED, it was lower in people with remitted versus active, and vice versa. These findings suggest an aver age shift toward restored methylation levels in people who are remitted. We found no significant differences between the NED and remitted groups. Table 2 lists the 28 common probes, along with corresponding genes and functions or phe notypes (derived from the National Center for Biotechnology Information gene database). Among these, we noted 2 genes relevant to psychiatric status or neurotransmitter function (HTR2B, CUEDC1); others associated with physiologic or immune functions (DSE, FCGR2A, HFM1, MCF2L2, MICAL2 , NOSIP, EML6); others with functions linked to nutritional status, insulin activity or energy metabolism (PRKAG2, RPTOR, SORBS1, ZFAND3, ZNF608); and a remainder associ ated with more general cellular or transcriptional processes (ANKIB1, AP2B1, KPNA1, GPR133, RAB32, SNX27, CDT1, CUX1, FTSJD2, MSI2). Note the observed connection between DSE and FCR2A and EhlerDanlos and autoimmune syn dromes, respectively. Associations between anorexia nervosa and EhlerDanlos, 37 rheumatoid arthritis and systemic lupus erythematosus 38 have been documented elsewhere.
Anorexia nervosa restrictive type versus anorexia nervosa binge/purge type versus NED
The results from 1way ANOVAs comparing probewise methylation levels for anorexia nervosa restrictive type ver sus anorexia nervosa binge/purge type versus NED compar isons, along with corresponding pairwise comparisons, can be found in Appendix 1, Table S3 . Although reduced n limits power, a 3group ANOVA identified 9 differentially methyl ated probes (at Q < 0.01). On many of these probes, pairwise comparisons were significant at Q < 0.01 and, allowing for effects at p < 0.05 (see superscripts in Appendix 1, Table S3 ), 8 of 9 probes were shared across anorexia nervosa restrictive type and anorexia nervosa binge/purge type. In all but 1 in stance, the indicated effect was consistent with increased methylation in anorexia nervosa. Many of the identified genes have been associated with disorderrelevant functions such as body mass and adiposity (ZNF608, CCDC146), diges tive function (NOSIP) and taste and olfaction (C2orf85).
Chronicity of illness
Findings (at Q < 0.01) that linked chronicity of illness to methylation status identified 64 probes mapping onto 55 genes (Appendix 1, Table S4 ). Among these were 3 probes related to the glutamate metabotropic receptor 2 (GRM2 [3 probes]). We also observed links to probes associated with genes that play a role in glia-neuron interactions (ICAM5, [5 probes]) and whitematter integrity/myelination (ASPA). Chronicity was also associated with the serotonin 2A recep tor (HTR2A). Finally, the analysis isolated probes related to wound healing (TNXB), taste (TAS1R3), insulin metabolism (IRS2, RPTOR), skeletal homeostasis (LRP5) and agerelated conditions (e.g., ELOVL2, FHL2). 39, 40 The direction of differ ences (on 39 of 64 [60.9%] differentially methylated probes) suggested a trend toward lower methylation in people with more chronic anorexia nervosa. Among identified genes, PRRT1, ZNRF2, RPTOR, NRXN2, SPTA1 and LRP5 were also isolated in the active versus remitted versus NED compari son described earlier.
Pre-/post-treatment changes in methylation
We found 73 probes (corresponding to 72 genes) at which the median change in BMI correlated with change in methylation at Q < 0.05 (and at Q < 0.01 on 8 probes; Appendix 1, Table S5 ). Differentially methylated probes included genes acting in cell growth (RPS6KA2), immune function (CLEC7A, IRAK3, TAP2, HHLA2) and inflammatory responses (NFKBIA, NR1H3). Other probes were associated with genes implicated in olfaction (OR4C45), lipid metabolism (PEBP4, NR1H3), insulin function (IGF2R) and a nicotinic acetylcholine recep tor (CHRNA5). One of the probes (corresponding to ASPA) was identified in the effects of chronicity described above. The direction of difference on 56 of 73 (76.7%) differentially methylated probes in the pre/post analysis showed that people who gained more weight during treatment tended to show larger increases in DNA methylation, implying that the direction of methylationlevel changes associated with weight gain was opposite to that associated with chronic ill ness exposure. Among the identified genes, ESM1, GTDC1, RNF39, EML6, RPS6KA2 and CUX1 were also identified in the active versus remitted versus NED comparison described earlier. Regressions examining associations with pre/post changes on the EDEQ total or subscale scores yielded no significant results.
Discussion
We examined genomewide methylation patterns in women with anorexia nervosa that was active or in stable remission, and in those who had no history of an eating disorder. In the active group, we also investigated methylation patterns as a function of chronicity of illness and treatmentlinked changes in BMI and eating symptoms.
Group comparisons
Participants in the active and NED groups showed many differentially methylated sites, with significant between group differences corresponding to genes implicated in metabolic and nutritional status (e.g., lipid, insulin and glucose metabolism), bone and tissue health, psychiatric status and immune function. At most differentially methyl ated probes, methylation levels were higher in the active group than the NED group, implying generally reduced expression of affected genes in actively ill partici pants. Comparisons between the active and remitted groups (the latter group presumed to represent suscepti bility to anorexia nervosa in the absence of active illness sequelae) identified a parallel set of genes implicated in lipid, glucose and insulin metabolism; bone and tissue health; serotonin function; and immune function. Notably, the directional tendency of effects complemented that obtained in the active versus NED comparisons; that is, methylation levels on affected probes were generally lower in the remitted group than in the active group. Like wise, effects on probes that were common to active versus NED and active versus remitted comparisons pointed in opposite directions. Together, the pattern of results sug gests methylation changes in people who are actively ill with anorexia nervosa -changes that can be "reset" by partial or full remission of illness. Similarly, findings that mainly differentiated people who were actively ill from those who were not currently ill (whether they had no eat ing disorder or were in remission from anorexia nervosa) leaned again toward the concept of DNA methylation being responsive to illness activity, rather than a stable, traitlike factor.
Correlational analyses
Consistent with the idea that many epigenetic changes con stitute illness sequelae, longer exposure to active illness seemed to coincide with more marked methylationlevel changes. Notably, the chronicity of illness was associated with methylation levels at genes associated with the function ing of 2 major neurotransmitters: glutamate and serotonin. Glutamate and serotonin systems have been implicated before in anorexia nervosa, 5, [41] [42] [43] and they are likely candi dates underlying anorexia nervosa's characteristic psychiatric manifestations. Moreover, findings isolated the serotonin2A receptor gene (HTR2A), a gene modulating affect, cognition and emotion regulation; 43, 44 HTR2A has been linked to anorexia nervosa in previous candidategene studies, 5 and in our own previous epigenomewide study. 26 Among the probes most strongly associated with illness duration, we found ELOVL2 and FHL2, both of which have been associated with epigenetic age and agerelated condi tions. 39, 40, 45, 46 It is an intuitive point that the length of a per son's exposure to anorexia nervosa is likely to be detrimental to their health prospects, and our findings suggest that sev eral adverse effects of this type may be epigenetically regu lated. Consistent with possible effects of the underconsump tion of nutrients implicated in DNA methylation, illness chronicity was inversely correlated with methylation levels at most of the implicated probes: greater duration of illness was associated with lower methylation. In contrast, longitudinal data indicated that BMI increases generally coincided with increases in methylationlevel changes at genes associated with lipid and glucose metabolism, immune and inflamma tory processes, and olfaction. Together, these results suggest that methylation levels may be responsive to short and long term alterations in illness status. If so, methylation measures could have promise as markers of illness staging.
We also want to comment on the possible disorderspecific relevance of differential methylation of 4 genes. We found that the presence and chronicity of illness was associated with methylation at probes related to the RPTOR gene, which influences cell growth in response to nutrients and insulin, and has been linked to such metabolic disorders as obesity and type 2 diabetes, and to the functioning of the gut microbiota. 47 We also found active illness to be associated with increased methylation at probes associated with the PRKAG2 gene. Lower methylation of PRKAG2 has been associated with higher BMI in a community sample. 48 In addition, similar to 2 previous studies in anorexia ner vosa, 26, 27 we found that TNXB methylation was associated with the presence of anorexia nervosa; the 2 previous studies reported that methylation at this gene was altered in people with anorexia nervosa. 26, 27 TNXB has been involved in connectivetissue disorders. Furthermore, the observed decreases in NR1H3 methylation posttreatment was in line with the results of 2 studies showing hyper methylation of this gene in active anorexia nervosa. 26, 27 Limitations Given the tissue specificity of DNA methylation, 49, 50 brain tissue is the optimal medium for epigenetic studies on men tal health entities. However, in the absence of postmortem brain banks for anorexia nervosa, studies such as ours must rely on biomaterials from peripheral tissues. Despite these limitations, however, epigenetic studies involving periph eral tissues can inform the understanding of processes in the brain. First, DNA methylation in the periphery may reflect a peripheral component of a bodywide somatic response to environmental signals that also alters methyla tion in the brain. 51 Second, various blood-brain mediators (e.g., glucocorticoids, cytokines such as IL1β) may link cen tral and peripheral effects. 49, 52 Third, on certain genes, there are relatively good correspondences between epigenetic markings obtained in blood and brain. [50] [51] [52] [53] [54] [55] Finally, unique disease relevant epigenetic markings in peripheral tissues, even if only partially representative of the effects in brain, may yet have clinical potential, 51 especially in the case of a disorder such as anorexia nervosa, which has widespread effects throughout the body.
Without measures of gene expression, our results cannot ascertain the functional significance of the altered methylation levels we observed. However, the literature affirms that methylation levels correspond to expression J Psychiatry Neurosci levels on many of the genes of interest found in this study, including HTR2A, 56 ICAM5, 57 CAMKK2, 58 CCR7, 59 ELOVL2 and FHL2. 60 Future investigations (including in vitro models to establish direct influences of changes in DNA methylation on gene expression) may help elucidate the actual functional significance of the identified genes. Finally, some of our findings may have been influenced by the effects of medication or substance use. Future replication of findings will, therefore, be a determinant.
Conclusion
Our findings have associated anorexia nervosa with epigen etic alterations bearing upon individuals' mental and phys ical status, metabolic functions and immunity, and also point to the likelihood (given that they tended to differentiate people with active anorexia nervosa from people in full or partial recovery from anorexia nervosa and from people without an eating disorder) that many of the alterations observed were reversible consequences of active illness. These findings are intriguing, because they may point to bio markers for disease staging or targets for innovations in nutritional or pharmacological treatments.
